Repository logo
 

Is hydroxychloroquine beneficial for COVID-19 patients?

Published version
Peer-reviewed

Type

Article

Change log

Authors

Li, Xing 
Wang, Ying 
Agostinis, Patrizia 
Rabson, Arnold 

Abstract

The outbreak of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first reported in December 2019. As similar cases rapidly emerged around the world1-3, the World Health Organization (WHO) declared a public health emergency of international concern on January 30, 2020 and pronounced the rapidly spreading coronavirus outbreak as a pandemic on March 11, 20204. The virus has reached almost all countries of the globe. As of June 3, 2020, the accumulated confirmed cases reached 6,479,405 with more than 383,013 deaths worldwide. The urgent and emergency care of COVID-19 patients calls for effective drugs, in addition to the beneficial effects of remdesivir5, to control the disease and halt the pandemic.

Description

Keywords

Adenosine Monophosphate, Alanine, Anti-Inflammatory Agents, Antiviral Agents, Betacoronavirus, COVID-19, Chloroquine, Coronavirus Infections, Cytokines, Humans, Hydroxychloroquine, Pandemics, Pneumonia, Viral, Risk, SARS-CoV-2, COVID-19 Drug Treatment

Journal Title

Cell Death Dis

Conference Name

Journal ISSN

2041-4889
2041-4889

Volume Title

11

Publisher

Springer Science and Business Media LLC